Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors

Mohamad Bassam Sonbol; Thorvardur R Halfdanarson

doi:10.1007/s11864-019-0670-1

Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors

Curr Treat Options Oncol. 2019 Aug 19;20(9):74. doi: 10.1007/s11864-019-0670-1.

Authors

Mohamad Bassam Sonbol¹, Thorvardur R Halfdanarson²

Affiliations

¹ Mayo Clinic Cancer Center, Phoenix, AZ, USA.
² Mayo Clinic Cancer Center, 200 1st St SW, Rochester, MN, 55905, USA. Halfdanarson.Thorvardur@mayo.edu.

PMID: 31428952
DOI: 10.1007/s11864-019-0670-1

Abstract

In 2017, the World Health Organization (WHO) classification for pancreatic NET was updated to include a new category of well-differentiated high-grade (Ki 67 > 20%) pancreatic tumors (NET G3), distinct from high-grade poorly differentiated neuroendocrine carcinoma (NEC). NET G3 are considered a molecularly, radiologically, and prognostically distinct entity compared to NEC and NET G1/G2. The optimal first-line management in NET G3 and sequencing therapies remains a challenge awaiting future trials taking into consideration the unique characteristics of this category. In this review, we aim to summarize the current evidence in the management of NET G3.

Keywords: High-grade; Neuroendocrine carcinoma; Neuroendocrine neoplasm; Neuroendocrine tumor; PRRT.

Publication types

Review

MeSH terms

Clinical Trials as Topic
Combined Modality Therapy / methods
Disease Management
Humans
Neoplasm Grading
Neuroendocrine Tumors / diagnosis*
Neuroendocrine Tumors / etiology
Neuroendocrine Tumors / therapy*
Treatment Outcome